Currently out of the existing stock ratings of Daniil Gataulin, 48 are a BUY (82.76%), 10 are a HOLD (17.24%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 16.4% that have a potential upside of 27.37% achieved within 125 days.

Daniil Gataulin’s has documented 106 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FBRX, Forte Biosciences at 24-Jun-2025.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on OTLK (OUTLOOK THERAPEUTICS INC).
The best stock recommendation documented was for OTLK (OUTLOOK THERAPEUTICS INC) at 8/15/2023. The price target of $10 was fulfilled within 15 days with a profit of $21 (67.74%) receiving and performance score of 45.16.

Average potential price target upside

of $13.78 (63.11%) on OTLK (OUTLOOK THERAPEUTICS INC).
of $12.66 (158.96%) on EYPT (EYEPOINT PHARMACEUTICALS).
of $12.5 (78.95%) on ADVM (ADVERUM BIOTECHNOLOGIES).

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics OTLK OUTLOOK THERAPEUTICS INC FBRX Forte Biosciences CGTX Cognition Therapeutics CRVO CervoMed OCS Oculis Holding AG Ordinary shares

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Graig Suvannavejh (MIZUHO)